Basilea joins INCATE to support antifungal innovation

Allschwil, Switzerland, January 13, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today

Kyivstar Launches 5G Pilot Program in Lviv

KYIV, Ukraine, Jan. 12, 2026 (GLOBE NEWSWIRE) — Kyivstar (Nasdaq: KYIV; KYIVW), Ukraine’s leading digital operator, has launched a 5G test zone in the historical center of Lviv, Ukraine. This

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related

Scroll to Top